Saluda Medical Inc (ASX: SLD) Share Price and News

Ms Livingstone is also the non-executive chair of Pacific National, and a non-executive director of the Australian Ballet and Quasar Satellite Technologies. She also served as a non-executive director of the Australian Design Council. From March 2016 to August 2022, Ms Livingstone served as a director of the Commonwealth Bank of Australia (ASX:CBA) and as chair of the board from January 2017 to August 2022. From June 1994 to October 2000, Ms Livingstone served as CEO of Cochlear Limited (ASX:COH), an implantable hearing medical device company.He is also a chair of risk committee.

Dr Brooke has over 30 years of healthcare venture capital management and investment experience. Dr Brooke has also served as director of Cynata Therapeutics Ltd (ASX:CYP) since May 2019, where he currently serves as the non-executive chair of the board, Actinogen Medical Ltd (ASX:ACW) since March 2017, where he currently serves as non-executive chair of the board, and Acrux Ltd (ASX:ACR) since June 2016. He is also a member of corporate Governance committee.

Mr Godshall is a seasoned executive with experience founding, funding, operating, and selling medical device companies. Since July 2024, Mr Godshall has served as chair of the board of directors of Galvanize Therapeutics, Inc, a biomedical platform company. In addition to his role with the Company, Mr Godshall was President, CEO and a director of Shockwave Medical Inc. (Shockwave) (NASDAQ:SWAV). Prior to Shockwave, from September 2006 to August 2016, Mr Godshall served as CEO of HeartWare International, Inc. (ASX:HIN and NASDAQ:HTWR), which was acquired by Medtronic plc. Mr Godshall also previously served as a director of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT).He is also a chair of corporate Governance committee.

Mr Faulkner has served as Managing Director of Redmile Group, LLC, a healthcare-focused investment firm. Mr Faulkner has also previously served as a director of Augmedix, Inc. (NASDAQ:AUGX) and served as chair of the board of Science 37 Holdings, Inc. from October 2021 until March 2024, and as chair of the board of MedAvail Holdings, Inc. from November 2020 until February 2024.He is also a member of risk committee.

Mr Palmisano has served as a director of RxSight, Inc., a commercial-stage medical technology company. Mr Palmisano also served as chair of the board of directors and CEO of Priveterra Acquisition Corp. from December 2020 until its business combination with AEON Biopharma, Inc. (AEON) in July 2023. Mr Palmisano remains a non-executive director of AEON. From September 2011 to November 2020, Mr Palmisano served as President and CEO of Wright Medical, a global medical device company, which was acquired by Stryker Corporation. Prior to Wright Medical, from 2008 to 2010, Mr Palmisano served as CEO of ev3 Inc., a global endovascular device company, which was acquired by Covidien plc. Prior to ev3, from 2003 to 2007, Mr Palmisano served as President and CEO of IntraLase Corp., an ophthalmic laser technology company, which was acquired by Advanced Medical Optics, Inc. Mr Palmisano previously served as chair of the board of Avedro, Inc. from June 2014 to June 2019.

Mr Blackford has served as the President and CEO of iRhythm Technologies, Inc., a Nasdaq-listed digital healthcare solutions company focused on the advancement of cardiac care, since October 2021. From September 2017 to September 2021, Mr Blackford held various roles, the recent one as the COO at Dexcom. From February 2009 to September 2017, Mr Blackford held various roles, the most recent one as the CFO at Nuvasive Inc., a medical device company for minimally invasive spine surgery. From June 1999 to September 2009, Mr Blackford was the director of finance and controller of the dental division at Zimmer Holdings, Inc., a medical device company. Mr Blackford has served as an independent member of the board of directors of Alphatec Holdings, Inc. since October 2017 and Paragon 28, Inc. since August 2022.

Mr Regan has over 30 years of experience in global operations, marketing, and executive management of both medical device and pharma/biotech companies. Prior to joining Saluda, Mr Regan served as Executive Vice President, Global Operations of Dexcom, Inc. (NASDAQ:DXCM), a medical device company (Dexcom). Mr Regan also served as Senior Vice President, Global Operations at Wright Medical Group N.V. (NASDAQ:WMGI) (Wright Medical), a global medical device company, which was acquired by Stryker Corporation. Mr Regan has held senior roles at Smith & Nephew plc, a medical technology company, and AbbVie Inc., a global, diversified research-based biopharmaceutical company. Mr Regan worked at Abbott Laboratories, in various operations leadership positions.He is also a member of corporate Governance committee.

-

-